Marksans Pharma shares surge on USFDA nod for diabetes drugs
At 2.47 pm, shares of Marksans Pharma were trading 10.71 per cent up at Rs 50.65.02-05-2016
02-05-2016
Marksans Pharma Limited announces USFDA approval for Metformin Hydrochloride Extended-Release (ER) Tablets USP 500mg and 750mg (ANDA 090295)
Marksans Pharma Ltd has informed BSE regarding a Press Release dated May 02, 2016, titled "Marksans Pharma Limited announces USFDA approval for Metformin Hydrochloride Extended-Release (ER) Tablets USP 500mg and 750mg (ANDA 090295)".02-05-2016
Shareholding for the Period Ended March 31, 2016
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here19-04-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Marksans Pharma Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.15-04-2016
Change in Directorate
Marksans Pharma Ltd has informed BSE that;1. The Board of Directors of the Company, at its meeting held on March 21, 2016, has appointed Dr. Vinay Gopal Nayak as an Additional Director of the Company.2. Dr. Balwant Shankarrao Desai has resigned as COO and Whole-time Director of the Company effective from March 21, 2016.3. The Board of Directors of the Company, at its meeting held on March 21, 2016, has also appointed Dr. Vinay...21-03-2016
Updates
Marksans Pharma Ltd has informed BSE that pursuant to the UK MHRA GMP inspection of the Marksans's Goa plant conducted from November 23, 2015 to November 25, 2015 and subsequent to the Company's response to the UK MHRA observations, the Company has received communication from UK MHRA informing that they are issuing a "Restricted GMP Certificate" allowing the Company to continue manufacture and marketing of critical products for the UK markets....17-03-2016
Financial Results, Limited Review Report, Results Press Release for December 31, 2015
Marksans Pharma Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20152. Consolidated Financial Results for the period ended December 31, 20153. Standalone Limited Review for the period ended December 31, 20154. Result Press Release for the period ended December 31, 201512-02-2016
Shareholding for the Period Ended December 31, 2015
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click here03-02-2016
Q3 numbers failing to prop up the stock prices
A depletion in market value of midcap and smallcap companies like InterGlobe, Kitex and Marksans has raised doubts over the valuations of their smaller peers.01-02-2016
Marksans Pharma up 10% after falling 40% in one week
The stock locked in upper circuit of 10% at Rs 63 on the BSE.19-01-2016